Skip to main content
. 2014 Dec 18;4(12):e006171. doi: 10.1136/bmjopen-2014-006171

Table 1.

Characteristics of patients with COPD by frequency of recorded exacerbation episodes during 12-month follow-up

Moderate-to-severe exacerbation frequency
None One Two or more
Patient characteristic n=31 049 n=14 189 n=13 351
Age, mean (SD) 69.3 (10.5) 69.8 (10.3) 69.4 (10.2)
Smoking status
 Current 10 531 (34) 4667 (33) 4173 (31)
 Former 15 988 (51) 7474 (53) 7345 (55)
 Never 3312 (11) 1492 (11) 1301 (10)
 Other 1218 (4) 556 (4) 532 (4)
Female 13 619 (44) 6831 (48) 6832 (51)
BMI underweight (<18.5 kg/m2) 1327 (4) 641 (5) 751 (6)
BMI normal (18.5–24.9 kg/m2) 10 533 (34) 4810 (34) 4668 (35)
BMI overweight (25.0–29.9 kg/m2) 10 633 (34) 4778 (34) 4274 (32)
BMI obese (≥30.0 kg/m2) 8037 (26) 3760 (26) 3472 (26)
Rate of moderate-to-severe exacerbations in prior 12 months/person/year, mean 0.37 0.74 1.67
Rate of exacerbations with hospital admission in prior 12 months/person/year, mean 0.07 0.12 0.2
Comorbidities any time in history
 Acute myocardial infarction 2530 (8) 1386 (10) 1350 (10)
 Congestive heart disease 1857 (6) 1041 (7) 1165 (9)
 Depression 3976 (13) 2116 (15) 2393 (18)
≥1 prescription within 12 months before cohort entry
 ICS 5789 (19) 2883 (20) 2501 (19)
 LABA 2379 (8) 1278 (9) 1295 (10)
 ICS/LABA 12 150 (39) 7328 (52) 9133 (68)
 LAMA 8618 (28) 5260 (37) 7049 (53)
MRC dyspnoea scale score
 MRC 1 6251 (23) 2059 (16) 1165 (10)
 MRC 2 11 552 (42) 4765 (38) 3546 (31)
 MRC 3 6478 (23) 3487 (28) 3286 (29)
 MRC 4 2959 (11) 1876 (15) 2605 (23)
 MRC 5 524 (2) 398 (3) 690 (6)
Airflow limitation grade
 Mild 5475 (18) 1971 (14) 1398 (10)
 Moderate 16 815 (54) 7324 (52) 5693 (43)
 Severe 7013 (23) 3855 (27) 4629 (35)
 Very severe 1152 (4) 814 (6) 1411 (11)

All data are n (%) unless otherwise stated. Percentages expressed as column %.

BMI, body mass index; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MRC, Medical Research Council.